Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q1 2023 Earnings Presentation
11 slides from Quanterix's earnings presentation, May 9, 2023
Slide 1: Q1 2023 Earnings Call
„ Q1 2023 Earnings Call MAY 9, 2023
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (a
Slide 3: Corporate Transformation: Progress on Assay Redevelopment Roadmap
Corporate Transformation: Progress on Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 CEO transition Strategic review Stability and Manufacturing Manufacturing Continued Optimized on April 25th completed in July, variance implementation implementatio
Slide 4: Q1 2023 Results vs PYQ1
Q1 2023 Results vs PYQ1 (in millions) Pharma OTHER INSTRUMENTS CONSUMABLES ACCELERATOR Q1 GAAP Q1 Non-GAAP Collaborations SERVICES* Revenue Mix 19% 49% 14% 5% 13% 2022 2023 2022 2023 Revenue 29.6 28.5 29.6 28.5 GAAP Revenue Q1 2022 Q1 2023 Gross Margin $ 14.6 16.9 12.8 15.1 -3% Gross Margin % 49.3%
Slide 5: Q1 2023 Cash & Cash Burn
Q1 2023 Cash & Cash Burn (in millions) -9.1 341.3 6.1 6.1 8.9 0.1 332.3 EO Q4 2022 Net Loss Non Working Capital CAPEX EO Q1 FY23 Cash Activities and Other Note: Ending total cash $332.3M; unrestricted cash balance $329.4M and restricted cash balance $2.9M 5
Slide 6: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Infectious Diseases Immunology & Oncology Others PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements # of units placed 549 Cumulative 2,282 538 908 46 876 2,141 133 46 480 98 130 47 98 236 46 5 41 3 225 708 335 403 44 197 73 193 1,575
Slide 7: 2023 Guidance
2023 Guidance We have made a modest, positive adjustment to our full year 2023 Revenue and Gross Margin % guidance Revenue (in millions) $105.5 $104 - $111 $4.5 Gross Margin % ~$11.0 Pharma Expect FY 2023 GAAP gross margin in the high 40s Collaboration(s) and non-GAAP gross margin in the mid 40s $99
Slide 8: FDA Accelerated Approval of Tofersen
FDA Accelerated Approval of Tofersen On the basis of Neurofilament light as a secondary end point Accelerated approval of Tofersen to treat genetic form of ALS VALOR and OLE Tofersen trials showed a substantial reduction (40-50%) in sNfL levels, indicative of reduction in neuronal injury FDA approva
Slide 9: pTau-217 emerges as the top blood-based biomarker for Alzheimer's
pTau-217 emerges as the top blood-based biomarker for Alzheimer's Growing consensus among the scientific community Expanding integration into therapeutic trial designs for enrollment & monitoring therapeutic response pTau-217 is so accurate it has the potential to replace PET for Dx Plasma pTau-217
Slide 10: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except pi GAAP gross profit $ 16926 $ 14559 $ 12592 $ 10944 $ g7ll $ 46806 $ a Shipping and handling costs (1) (1,829) (1,781) (1.926) (1.636) (1,868) (7.206) (6.892) Non-GAAP
Slide 11: Leader in proteomics, positioning ourselves to accelerate faster
Most Sensitive Protein Measurements in Blood Strong IP protection Translational Leader FDA - BTD pTau181, NfL LDT implementation Pharma / KOL partnerships Sample to Answer Platform Rapid TAT; global footprint Continued Innovation Simoa in every lab, menu expansion, pushing limits of sensitivity furt